[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”full_width” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern”][vc_column][vc_column_text]
2008 年 12 月 1 日
LA JOLLA, Calif.–(BUSINESS WIRE)–Novelix Pharmaceuticals, Inc. (Novelix), a biopharmaceutical company developing small molecule cancer therapeutics, announced today that it has selected the large-market indication of actinic keratosis (AK) as the main focus of the company’s dermatology development program. NVX-207, a targeted therapeutic regulating caspase-9, has shown itself to be ideally suited for topical treatment. Strong patents covering the composition of the drug candidate issued recently in the US and China. Over 30 European countries are expected to issue additional patents in January 2009.[/vc_column_text][vc_empty_space][button size=”large” target=”_blank” hover_type=”default” text=”Read Article” link=”https://www.businesswire.com/news/home/20081201006193/en/Novelix-Pharmaceuticals-Initiates-Actinic-Keratosis-Drug-Development”][vc_separator type=”normal” color=”#cccccc” thickness=”1″ up=”50″ down=”50″][/vc_column][/vc_row]